Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Standard BioTools Inc (NASDAQ: LAB) was $2.13 for the day, up 2.40% from the previous closing price of $2.08. In other words, the price has increased by $2.40 from its previous closing price. On the day, 2.22 million shares were traded. LAB stock price reached its highest trading level at $2.16 during the session, while it also had its lowest trading level at $2.07.
Ratios:
Our analysis of LAB’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.53 and its Current Ratio is at 3.88. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, TD Cowen on April 16, 2024, initiated with a Buy rating and assigned the stock a target price of $3.50.
On April 04, 2024, Jefferies started tracking the stock assigning a Buy rating and target price of $3.25.
On July 12, 2023, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $4.KeyBanc Capital Markets initiated its Overweight rating on July 12, 2023, with a $4 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 27 ’24 when Casdin Partners Master Fund, L bought 250,000 shares for $2.19 per share. The transaction valued at 546,750 led to the insider holds 54,025,821 shares of the business.
Casdin Partners Master Fund, L bought 292,100 shares of LAB for $620,975 on Aug 23 ’24. The Director now owns 53,625,821 shares after completing the transaction at $2.13 per share. On Aug 22 ’24, another insider, Casdin Partners Master Fund, L, who serves as the Director of the company, bought 307,900 shares for $1.96 each. As a result, the insider paid 602,807 and bolstered with 53,333,721 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LAB now has a Market Capitalization of 790558016 and an Enterprise Value of 246465760. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.80 while its Price-to-Book (P/B) ratio in mrq is 1.55. Its current Enterprise Value per Revenue stands at 1.808 whereas that against EBITDA is -2.363.
Stock Price History:
Over the past 52 weeks, LAB has reached a high of $3.16, while it has fallen to a 52-week low of $1.21. The 50-Day Moving Average of the stock is 10.67%, while the 200-Day Moving Average is calculated to be -7.32%.
Shares Statistics:
LAB traded an average of 3.35M shares per day over the past three months and 2314430 shares per day over the past ten days. A total of 371.15M shares are outstanding, with a floating share count of 359.39M. Insiders hold about 3.17% of the company’s shares, while institutions hold 72.58% stake in the company. Shares short for LAB as of 1723680000 were 21804697 with a Short Ratio of 6.51, compared to 1721001600 on 19449968. Therefore, it implies a Short% of Shares Outstanding of 21804697 and a Short% of Float of 12.100001.
